brand-name pharmaceutical

One of the key issues is whether the U.S. Court of Appeals for the Federal Circuit needs to give deference to lower federal courts when it hears appeals on patents, and considers patent claim construction.

A new Federal Trade Commission (FTC) report found an increase in pay-for-delay deals, in which brand-name pharmaceutical companies settle patent litigation with generic-drug companies by reaching agreements that delay the release of cheaper drugs to market.